Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 291 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Antidepressant + placebo Clear all
Completed Phase 2 Interventional Results available

Efficacy of Antidepressants in Chronic Back Pain

NCT00964886
View directory record Official record
Conditions
Back Pain
Interventions
cognitive behavioral therapy, desipramine hydrochloride, benztropine mesylate 0.125 mg daily
Behavioral · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Sep 24, 2026, 4:02 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

NCT06524830
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
VLS-01-203 BU, VLS-01-BU Placebo
Drug
Lead sponsor
atai Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
34
States / cities
Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 24, 2026, 4:02 PM EDT
Recruiting Phase 2 Interventional

Escitalopram in Asthma Patients With Frequent Exacerbation

NCT06216535
View directory record Official record
Conditions
Asthma
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 4 Interventional Results available

Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression

NCT01670019
View directory record Official record
Conditions
Major Depressive Disorder Without Psychotic Features
Interventions
Asenapine 5-20 mg daily, Placebo 1-4 tablets daily
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Augusta, Georgia • Durham, North Carolina • Greenville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Sep 24, 2026, 4:02 PM EDT
Terminated Phase 2 Interventional Results available

A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression

NCT04423757
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
BI 1358894, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 3 Interventional

A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression

NCT00429260
View directory record Official record
Conditions
Depressive Disorder
Interventions
Saredutant
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Malvern, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Sep 24, 2026, 4:02 PM EDT
Terminated Phase 3 Interventional Results available

Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder

NCT00868374
View directory record Official record
Conditions
Major Depressive Disorder, Generalized Anxiety Disorder
Interventions
Quetiapine XR, Placebo
Drug
Lead sponsor
Keming Gao
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability of Riluzole in Treatment Resistant Depression

NCT01204918
View directory record Official record
Conditions
Depression
Interventions
Riluzole, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
New Haven, Connecticut • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 4 Interventional

Physiologic Monitoring of Antidepressant Response

NCT00792168
View directory record Official record
Conditions
Major Depression
Interventions
venlafaxine (Effexor), placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1998
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI

NCT00539240
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Rabeprazole 20mg, placebo dinner and bedtime, Rabeprazole 20 mg two times, Placebo at bedtime, Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Sep 24, 2026, 4:02 PM EDT
Recruiting Phase 2 Interventional

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

NCT06511908
View directory record Official record
Conditions
Suicide, Depressive Disorder, Treatment-Resistant, Ketamine, Molecular Mechanisms of Pharmacological Action, Neurotransmitter Agents, Excitatory Amino Acid Agents, Physiological Effects of Drugs, Depressive Disorder, Major, Depressive Disorder, Depression, Mental Disorders, Mood Disorders, Behavioral Symptoms
Interventions
(2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg), Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Sertraline and Cognitive Behavioral Therapy in Treating Pediatric Obsessive-Compulsive Disorder

NCT00382291
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Regular Titration, Placebo, Slow Titration
Drug
Lead sponsor
University of Florida
Other
Eligibility
7 Years to 17 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Gainesville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2013 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 4 Interventional Results available

Project to Improve Symptoms and Mood in People With Spinal Cord Injury

NCT00592384
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymia, Spinal Cord Injuries
Interventions
venlafaxine XR, placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 64 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Birmingham, Alabama • Miami, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2014 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder

NCT03193398
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
BTRX-246040 oral capsule(s), Placebo oral capsule(s)
Drug
Lead sponsor
BlackThorn Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Cerritos, California • Garden Grove, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

NCT01364649
View directory record Official record
Conditions
Treatment Outcome
Interventions
Vortioxetine, Escitalopram, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
53
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Sep 24, 2026, 4:02 PM EDT
Terminated Phase 2 Interventional Results available

A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression

NCT01098240
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CP-601,927, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
58
States / cities
Little Rock, Arkansas • Beverly Hills, California • Garden Grove, California + 44 more
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

NCT06419608
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
62
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

NCT03968159
View directory record Official record
Conditions
Adjunctive Treatment of Major Depressive Disorder
Interventions
Pimavanserin, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
41
States / cities
Birmingham, Alabama • Garden Grove, California • Glendale, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Sep 24, 2026, 4:02 PM EDT
Recruiting Phase 2 Interventional

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

NCT06591091
View directory record Official record
Conditions
Depression
Interventions
Clemastine Fumarate, Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 24, 2026, 4:02 PM EDT
Recruiting Phase 3 Interventional

Lumateperone for Late-Life Depression

NCT07623135
View directory record Official record
Conditions
Treatment Resistant Depression (TRD), Late Life Depression (LLD), Depression / Major Depressive Disorder
Interventions
Lumateperone, Placebo
Drug
Lead sponsor
Eric Lenze
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Tucson, Arizona • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression

NCT01407094
View directory record Official record
Conditions
Depression
Interventions
Sertraline, Placebo, BupropionXL
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
296 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Sep 24, 2026, 4:02 PM EDT
Not yet recruiting Phase 2 Interventional

A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder

NCT07772531
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
BMS-986511, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
21
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression

NCT00953745
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Aripiprazole, Placebo Capsule, Placebo Tablet
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Neurotrophic Factors and Depression

NCT00812994
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
22 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2008 · Synced Sep 24, 2026, 4:02 PM EDT